SCHEMBL990717

SCHEMBL990717

CN1CCN(c2cc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c(C(F)(F)F)cn2)CC1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKCA P17252 9/20 0.66
PRKCQ Q04759 9/20 0.66
PRKCB P05771 8/20 0.66
PRKCH P24723 8/20 0.66
PRKCE Q02156 8/20 0.66
PRKCD Q05655 8/20 0.66
JAK3 P52333 13/20 0.58
JAK1 P23458 7/20 0.58
JAK2 O60674 5/20 0.58
TYK2 P29597 3/20 0.58
GSK3B P49841 2/20 0.56
PDPK1 O15530 1/20 0.56
DYRK3 O43781 1/20 0.56
PRKD3 O94806 1/20 0.56
MAP4K4 O95819 1/20 0.56
ABL1 P00519 1/20 0.56
EGFR P00533 1/20 0.56
ERBB2 P04626 1/20 0.56
PRKCG P05129 1/20 0.56
FYN P06241 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL990670 0.87 PRKCH (0.71) PRKCAPRKCQPRKCBPRKCHPRKCE
SCHEMBL990023 0.86 PRKCA (0.57) PRKCAPRKCQPRKCBPRKCHPRKCE
SCHEMBL992515 0.86 PRKCH (0.69) PRKCAPRKCQPRKCBPRKCHPRKCE
SCHEMBL21583796 0.84 JAK3 (0.81) PRKCAPRKCQPRKCBPRKCHPRKCE
SCHEMBL4906489 0.84 JAK3 (0.82) PRKCAPRKCQPRKCBPRKCHPRKCE
SCHEMBL857150 0.83 PRKCQ (0.72) PRKCAPRKCQPRKCBPRKCHPRKCE
SCHEMBL991233 0.83 PRKCH (0.65) PRKCAPRKCQPRKCBPRKCHPRKCE
SCHEMBL989017 0.81 PRKCA (0.66) PRKCAPRKCQPRKCBPRKCHPRKCE
SCHEMBL4377883 0.80 PRKCH (1.00) PRKCAPRKCQPRKCBPRKCHPRKCE
SCHEMBL5460152 0.80 PRKCA (0.68) PRKCAPRKCQPRKCBPRKCHPRKCE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2270001-A1 Indolylmaleimide derivatives as PKC inhibitors Novartis AG (CH) 2011-01-05 EP claimed
US-7648989-B2 Indolylmaleimide derivatives as PKC inhibitors NOVARTIS AG (CH) 2010-01-19 US claimed
US-20080242675-A1 Indolylmaleimide Derivatives as Pkc Inhibitors NOVARTIS AG (CH) 2008-10-02 US claimed
JP-2007518731-A 2007-07-12 JP claimed
EP-1745037-A1 INDOLYLMALEIMIDE DERIVATIVES AS PKC INHIBITORS Novartis AG (CH) 2007-01-24 EP claimed
WO-2005068455-A1 INDOLYLMALEIMDE DERIVATIVES AS PKC INHIBITORS NOVARTIS AG (CH) 2005-07-28 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080242675-A1 Indolylmaleimide Derivatives as Pkc Inhibitors PRKCE, PRKCH, PRKCI PRKCA 4/4885PRKCQ 8/4885PRKCB 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.